Talquetamab, a Novel Anti-Myeloma GPRC5DxCD3 Bispecific Antibody, is Associated with Increased Oropharyngeal FDG Uptake

被引：0
|
作者：
Trak, J. [1 ]
Mouhieddine, T. [1 ]
Lancman, G. [1 ]
Sanchez, L. [1 ]
Chari, A. [1 ]
Ghesani, M. [1 ]
机构：
[1] Mt Sinai Hosp, New York, NY USA
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2023年 / 50卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
EP-0351
引用
收藏
页码：S571 / S571
页数：1
相关论文
共 50 条
  • [41] RG6234: A Novel 2:1 GPRC5D T Cell Bispecific Antibody Exhibits Best in Class Potential for the Treatment of Multiple Myeloma As a Monotherapy and in Combination
    Eckmann, Jan
    Fauti, Tanja
    Zabaleta, Aintzane
    Blanco, Laura
    Kassem, Sahar
    Carrie, Nadege
    Lorenz, Stefan
    Carpy, Alejandro
    Christopeit, Tony
    Fertig, Georg
    Bernasconi, Luise
    Biehl, Marlene
    Diggelmann, Sarah
    Knobloch, Melanie
    Mayoux, Maud
    Dumontet, Charles
    Paiva, Bruno
    Martinet, Ludovic
    Leclair, Stephane
    Xu, Wei
    Klein, Christian
    Umana, Pablo
    BLOOD, 2022, 140 : 2091 - 2092
  • [42] BR109, a Novel Fully Humanized T-Cell-Engaging Bispecific Antibody with GPRC5D Binding, Has Potent Antitumor Activities in Multiple Myeloma
    Liu, Ying
    Zhou, Ya-Qiong
    Nie, Lei
    Zhu, Shan-Shan
    Li, Na
    Wu, Zhen-Hua
    Wang, Qi
    Qi, Jian
    Wu, Bing-Yuan
    Chen, Shu-Qing
    Wang, Hai-Bin
    CANCERS, 2023, 15 (24)
  • [43] Evaluation of Drug-Drug Interaction Potential of Talquetamab, a T-Cell-Redirecting GPRC5D x CD3 Bispecific Antibody, as a Result of Cytokine Release Syndrome in Patients with Relapsed/Refractory Multiple Myeloma in MonumenTAL-1, Using a Physiologically Based Pharmacokinetic Model
    Willemin, Marie-Emilie
    Gong, Jue
    Hilder, Brandi W.
    Masterson, Tara
    Tolbert, Jaszianne
    Renaud, Thomas
    Heuck, Christoph
    Kane, Colleen
    De Zwart, Loeckie
    Girgis, Suzette
    Ma, Xuewen
    Ouellet, Daniele
    TARGETED ONCOLOGY, 2024, 19 (06) : 965 - 979
  • [44] Pre-clinical development of a novel anti-GPRC5D inducing potent anti-tumor effect through enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) for multiple myeloma
    Bonnevaux, Helene
    Remy, Elisabeth
    Pizette, Theo
    Bouvier, Sophie
    Desrumeaux, Klervi
    Bassinet, Laurent
    Nicolazzi, Celine
    Rettman, Pauline
    Klippel, Zandra
    Meloni, Marco
    Chiron, Marielle
    Virone-Oddos, Angela
    CANCER RESEARCH, 2024, 84 (06)
  • [45] TARGETING MYELOMA STEM CELLS WITH T CELLS ARMED WITH ANTI-CD3 X ANTI-CD20 BISPECIFIC ANTIBODY (CD20BI) PRIOR TO ASCT LEADS TO DEVELOPMENT OF ANTI-MYELOMA IMMUNE RESPONSES POST AUTOLOGOUS STEM CELL TRANSPLANT THAT CAN BE BOOSTED WITH TARGETED T CELLS
    Lawrence, L. G.
    Archana, T.
    Muneer, A.
    Zaid, A-K
    Voravit, R.
    Jeffrey, Z.
    Lois, A.
    Elyse, P. N.
    Dana, S.
    Patricia, S. A.
    Karen, M.
    Joseph, U. P.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012, 18 (02) : S259 - S259
  • [46] Talquetamab, a G protein-coupled receptor family C group 5 member D x CD3 bispecific antibody, in relapsed/refractory multiple myeloma: efficacy and safety of patient subgroups from monumenTAL-1
    Krishnan, Amrita
    Costa, Luciano
    Schinke, Carolina
    Karlin, Lionel
    Morillo, Daniel
    Martinez-Chamorro, Carmen
    Ye, Jing Christine
    Chari, Ajai
    Moreau, Philippe
    Caers, Jo
    Jakubowiak, Andrzej
    Campagna, Michela
    Masterson, Tara
    Hilder, Brandi
    Tolbert, Jaszianne
    Renaud, Thomas
    Smit, M. Damiette
    Heuck, Christoph
    Minnema, Monique
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S45 - S46
  • [47] Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell-recruiting Antibody Optimized for Cytotoxicity and Cytokine Release
    de Zafra, Christina L. Zuch
    Fajardo, Flordeliza
    Zhong, Wendy
    Bernett, Matthew J.
    Muchhal, Umesh S.
    Moore, Gregory L.
    Stevens, Jennitte
    Case, Ryan
    Pearson, Joshua T.
    Liu, Siyuan
    McElroy, Patricia L.
    Canon, Jude
    Desjarlais, John R.
    Coxon, Angela
    Balazs, Mercedesz
    Nolan-Stevaux, Olivier
    CLINICAL CANCER RESEARCH, 2019, 25 (13) : 3921 - 3933
  • [48] Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 Results from MonumenTAL-1
    Chari, Ajai
    Touzeau, Cyrille
    Schinke, Carolina
    Minnema, Monique C.
    Berdeja, Jesus
    Oriol, Albert
    Van de Donk, Niels W. C. J.
    Rodriguez Otero, Paula
    Askari, Elham
    Mateos, Maria-Victoria
    Costa, Luciano J.
    Caers, Jo
    Rasche, Leo
    Krishnan, Amrita Y.
    Vishwamitra, Deeksha
    Ma, Xuewen
    Qin, Xiang
    Gries, Katharine S.
    Campagna, Michela
    Masterson, Tara
    Hilder, Brandi
    Tolbert, Jaszianne
    Renaud, Thomas
    Goldberg, Jenna D.
    Heuck, Christoph
    San-Miguel, Jesus
    Moreau, Philippe
    BLOOD, 2022, 140
  • [49] Efficacy and safety of talquetamab, a G protein-coupled receptor family C group 5 member D x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): Updated results from MonumenTAL-1.
    Minnema, Monique C.
    Krishnan, Amrita Y.
    Berdeja, Jesus G.
    Rocafiguera, Albert Oriol
    van de Donk, Niels W. C. J.
    Rodriguez-Otero, Paula
    Morillo, Daniel
    Mateos, Maria-Victoria
    Costa, Luciano J.
    Caers, Jo
    Vishwamitra, Deeksha
    Ma, Joanne
    Yang, Shiyi
    Hilder, Brandi
    Tolbert, Jaszianne A.
    Goldberg, Jenna D.
    Chari, Ajai
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [50] An Uniquely Designed Asymmetric Bispecific Antibody Against GPRC5D and CD3 (LBL-034) in Patients with Relapsed/Refractory Multiple Myeloma: A Phase I/II, First in Human, Open-Label, Multicenter, Dose Escalation/Expansion Study
    Qin, Ling
    Zhong, Yuping
    Huang, Dongping
    Xie, Haitang
    Du, Xin
    Liao, Aijun
    Zhang, Hongli
    Cai, Shengli
    Lu, Jin
    BLOOD, 2024, 144 : 4736 - 4737
12345